Organovo (NASDAQ:ONVO) Upgraded by ValuEngine to “Hold”
A number of other equities research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Organovo from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Thursday, November 14th. HC Wainwright downgraded shares of Organovo from a “buy” rating to a “neutral” rating in a research note on Thursday, August 8th.
ONVO stock opened at $0.51 on Tuesday. The company has a market capitalization of $65.75 million, a PE ratio of -2.22 and a beta of 2.22. Organovo has a 52 week low of $0.22 and a 52 week high of $1.18. The company’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.40.
A number of institutional investors have recently made changes to their positions in ONVO. Advisor Group Inc. grew its stake in Organovo by 67.0% during the second quarter. Advisor Group Inc. now owns 87,250 shares of the medical research company’s stock worth $45,000 after buying an additional 35,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Organovo in the 2nd quarter valued at approximately $208,000. Paloma Partners Management Co acquired a new stake in shares of Organovo in the 2nd quarter valued at approximately $283,000. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Organovo by 106.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,122,465 shares of the medical research company’s stock valued at $2,156,000 after purchasing an additional 2,126,149 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Organovo by 45.3% in the 2nd quarter. Renaissance Technologies LLC now owns 5,327,139 shares of the medical research company’s stock valued at $2,786,000 after purchasing an additional 1,661,998 shares in the last quarter. Hedge funds and other institutional investors own 47.95% of the company’s stock.
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Story: Moving Average (MA)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.